Long-Acting Injectable Cabotegravir and Rilpivirine in a Pregnant Woman With HIV

Clin Infect Dis. 2024 Dec 17;79(6):1468-1471. doi: 10.1093/cid/ciae242.

Abstract

This case report describes the effects of bimonthly long-acting injectable cabotegravir (CAB)/RPV before and throughout pregnancy. CAB concentrations were comparable to those in nonpregnant individuals; RPV concentrations were 70%-75% lower. No virologic failure or vertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly long-acting injectable CAB/RPV may not be suitable for pregnant women, and monitoring of exposed infants is warranted.

Keywords: HIV; cabotegravir; long-acting injectables; pregnancy; rilpivirine.

Publication types

  • Case Reports

MeSH terms

  • Adult
  • Anti-HIV Agents* / administration & dosage
  • Anti-HIV Agents* / therapeutic use
  • Diketopiperazines
  • Female
  • HIV Infections* / drug therapy
  • Humans
  • Pregnancy
  • Pregnancy Complications, Infectious* / drug therapy
  • Pregnancy Complications, Infectious* / virology
  • Pyridones* / administration & dosage
  • Pyridones* / therapeutic use
  • Rilpivirine* / administration & dosage
  • Rilpivirine* / therapeutic use

Substances

  • cabotegravir
  • Pyridones
  • Rilpivirine
  • Anti-HIV Agents
  • Diketopiperazines